Pemvidutide
A dual glucagon and GLP-1 agonist studied for obesity and serious liver disease.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A dual glucagon and GLP-1 agonist studied for obesity and serious liver disease.
Investigational; not FDA-approved for the uses discussed.
Histology or digital-pathology changes do not prove fewer liver failures or deaths.
Why It's Being Studied
- Obesity research
- MASH research
- Liver fat
Mechanism of Action
GLP-1 and glucagon-receptor signalling is intended to influence appetite, energy metabolism and liver fat.
GLP-1 and glucagon-receptor signalling is intended to influence appetite, energy metabolism and liver fat. Histology or digital-pathology changes do not prove fewer liver failures or deaths.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity research
- MASH research
- Liver fat
- Subcutaneous clinical research
Evidence Summary
MOMENTUM reported weight reduction; IMPACT provides phase 2b human MASH histology and marker data.
Higher tiers carry more weight. Filled tiers have evidence for Pemvidutide; tap to read it.
- MOMENTUM reported weight reduction; IMPACT provides phase 2b human MASH histology and marker data.
1 cited sources.
- Regulatory document1
Human clinical evidence
- MOMENTUM reported weight reduction; IMPACT provides phase 2b human MASH histology and marker data.
Reported Adverse Events in Research
- Gastrointestinal tolerability and long-term safety remain important; liver-disease populations require specialist assessment.
Limitations of Current Evidence
- Histology or digital-pathology changes do not prove fewer liver failures or deaths.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Pemvidutide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Pemvidutide — regulatory document